BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26013168)

  • 1. PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
    Ono H; Basson MD; Ito H
    Mol Cancer Res; 2015 Aug; 13(8):1174-84. PubMed ID: 26013168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.
    Ewald B; Sampath D; Plunkett W
    Mol Cancer Ther; 2007 Apr; 6(4):1239-48. PubMed ID: 17406032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
    Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
    Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling.
    Ono H; Basson MD; Ito H
    PLoS One; 2014; 9(5):e96060. PubMed ID: 24788754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pim-3 contributes to radioresistance through regulation of the cell cycle and DNA damage repair in pancreatic cancer cells.
    Chen XY; Wang Z; Li B; Zhang YJ; Li YY
    Biochem Biophys Res Commun; 2016 Apr; 473(1):296-302. PubMed ID: 27016481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Petite Integration Factor 1 knockdown enhances gemcitabine sensitivity in pancreatic cancer cells via increasing DNA damage.
    Wang K; Hua X; Fu X; Hao Z; Jiao A; Li S
    J Appl Toxicol; 2023 Oct; 43(10):1522-1532. PubMed ID: 37183367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
    Kawamura D; Takemoto Y; Nishimoto A; Ueno K; Hosoyama T; Shirasawa B; Tanaka T; Kugimiya N; Harada E; Hamano K
    Oncol Rep; 2017 Nov; 38(5):3238-3244. PubMed ID: 29048622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer.
    Zhou Y; Zheng M; Liu Z; Yang H; Zhu P; Jiang JL; Tang J; Chen ZN
    Biochem Biophys Res Commun; 2020 Jul; 528(1):62-70. PubMed ID: 32456796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma.
    Ma S; Bao JYJ; Kwan PS; Chan YP; Tong CM; Fu L; Zhang N; Tong AHY; Qin YR; Tsao SW; Chan KW; Lok S; Guan XY
    Gastroenterology; 2012 Sep; 143(3):675-686.e12. PubMed ID: 22705009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
    Zhang Z; Wang F; Du C; Guo H; Ma L; Liu X; Kornmann M; Tian X; Yang Y
    Cancer Lett; 2017 Aug; 402():213-224. PubMed ID: 28602977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis.
    Schniewind B; Christgen M; Kurdow R; Haye S; Kremer B; Kalthoff H; Ungefroren H
    Int J Cancer; 2004 Mar; 109(2):182-8. PubMed ID: 14750167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G
    Peng T; Dou QP
    J Cell Biochem; 2017 Sep; 118(9):2722-2730. PubMed ID: 28165150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting protein tyrosine kinase 6 enhances apoptosis of colon cancer cells following DNA damage.
    Gierut JJ; Mathur PS; Bie W; Han J; Tyner AL
    Mol Cancer Ther; 2012 Nov; 11(11):2311-20. PubMed ID: 22989419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer.
    Mathur PS; Gierut JJ; Guzman G; Xie H; Xicola RM; Llor X; Chastkofsky MI; Perekatt AO; Tyner AL
    Mol Cancer Res; 2016 Jun; 14(6):563-73. PubMed ID: 26983689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
    Köpper F; Binkowski AM; Bierwirth C; Dobbelstein M
    Cell Cycle; 2014; 13(6):884-9. PubMed ID: 24556918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
    Ewton DZ; Hu J; Vilenchik M; Deng X; Luk KC; Polonskaia A; Hoffman AF; Zipf K; Boylan JF; Friedman EA
    Mol Cancer Ther; 2011 Nov; 10(11):2104-14. PubMed ID: 21878655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.